Optimization of 1,2,4-triazolopyridines as inhibitors of human 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD-1)

ACS Medicinal Chemistry Letters

Volumn 5, Issue 7, 2014, Pages 803-808

  Li, Jun ^a   Kennedy, Lawrence J ^a   Wang, Haixia ^a   Li, James J ^a   Walker, Steven J ^a   Hong, Zhenqiu ^a   Oconnor, Stephen P ^a   Nayeem, Akbar ^a   Camac, Daniel M ^a   Morin, Paul E ^a   Sheriff, Steven ^a   Wang, Mengmeng ^a   Harper, Timothy ^a   Golla, Rajasree ^a   Seethala, Ramakrishna ^a   Harrity, Thomas ^a   Ponticiello, Randolph P ^a   Morgan, Nathan N ^a   Taylor, Joseph R ^a   Zebo, Rachel ^a   Gordon, David A ^a   Robl, Jeffrey A ^a   more..

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Enzyme inhibitors; human 11 hydroxysteroid dehydrogenase type 1; triazolopyridines

Indexed keywords

1,2,4 TRIAZOLOPYRIDINE; 11BETA HYDROXYSTEROID DEHYDROGENASE 1; OXIDOREDUCTASE INHIBITOR; PREGNANE X RECEPTOR; PYRIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; DRUG BINDING; DRUG POTENCY; DRUG SYNTHESIS; HUMAN; HYDROGEN BOND; LIPOPHILICITY; PHARMACOPHORE; PRIORITY JOURNAL; TRANSACTIVATION; X RAY CRYSTALLOGRAPHY;

EID: 84904337273     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml500144h     Document Type: Article

References (27)

1. Tomlinson, J. W.; Stewart, P. M. Mechanisms of disease: selective inhibition of 11β-hydroxysteroid dehydrogenase type 1 as a novel treatment for the metabolic syndrome Nat. Clin. Practice Endocrinol. Metab. 2005, 1, 92-99
2. Gathercole, L. L.; Lavery, G. G.; Morgan, S. A.; Cooper, M. S.; Sinclair, A. J.; Tomlinson, J. W.; Stewart, P. M. 11β-Hydroxysteroid dehydrogenase 1: translational and therapeutic aspects Endocrine Rev. 2013, 34 (4) 525-555
3. Morton, N. M. Obesity and corticosteroids: 11β-hydroxysteroid type 1 as a cause and therapeutic target in metabolic disease Mol. Cell. Endocrinol. 2010, 316, 154-164
4. Oltmanns, K. M.; Dodt, B.; Schultes, B.; Raspe, H. H.; Schweiger, U.; Born, J.; Fehm, H. L.; Peters, A. Cortisol correlates with metabolic disturbances in a population study of type 2 diabetic patients Eur. J. Endocrinol. 2006, 154, 325-331
5. Jamieson, P. M.; Walker, B. R.; Chapman, K. E.; Rossiter, S.; Seckl, J. R. 11β-Hydroxysteroid dehydrogenase type 1 is a predominant 11β reductase in the intact perfused rat liver J. Endocrinol. 2000, 165, 685-692
6. Masuzaki, H.; Paterson, J.; Shinyama, H.; Morton, N. M.; Mullins, J. J.; Seckl, J. R.; Flier, J. S. A transgenic model of visceral obesity and the metabolic syndrome Science 2001, 294, 2166-2170
7. Masuzaki, H.; Yamamoto, H.; Kenyon, C. J.; Elmquist, J. K.; Morton, N. M.; Paterson, J. M.; Shinyama, H.; Sharp, M. G. F.; Fleming, S.; Mullins, J. J.; Seckl, J. R.; Flier, J. S. Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice J. Clin. Invest. 2003, 112, 83-90
8. Morton, N. M.; Holmes, M. C.; Fievet, C.; Staels, B.; Tailleux, A.; Mullins, J. J.; Seckl, J. R. Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11β-hydroxysteroid dehydrogenase type 1 null mice J. Biol. Chem. 2001, 276, 41293-41300
9. Fotsch, C.; Wang, M. Blockade of glucocorticoid excess at the tissue level: inhibitors of 11β-hydroxysteroid dehydrogenase type 1 as a therapy for type 2 diabetes J. Med. Chem. 2008, 51, 4851-4857
10. Boyle, C. D.; Kowalski, T. J. 11β-Hydroxysteroid dehydrogenase type 1 inhibitors: a review of recent patents Expert Opin. Ther. Pat. 2009, 19, 801-825
11. Ge, R.; Huang, Y.; Liang, G.; Li, X. 11β-Hydroxysteroid dehydrogenase type 1 inhibitors as promising therapeutic drugs for diabetes: status and development Curr. Med. Chem. 2010, 17, 412-422
12. Veniant, M. M.; Hale, C.; Hungate, R. W.; Gahm, K.; Emery, M. G.; Jona, J.; Joseph, S.; Adams, J.; Hague, A.; Moniz, G.; Zhang, J.; Bartberger, M. D.; Li, V.; Syed, R.; Jordan, S.; Komorowski, R.; Chen, M. M.; Cupples, R.; Kim, K. W.; St. Jean, D. J., Jr.; Johansson, L.; Henriksson, M. A.; Williams, M.; Vallgarda, J.; Fotsch, C.; Wang, M. Discovery of a potent, orally active 11β-hydroxysteroid dehydrogenase type 1 inhibitor for clinical study: Identification of (S)-2-((1 S,2 S,4 R)-bicyclo[2.2.1]heptan-2-ylamino)-5- isopropyl-5-methylthiazol-4(5 H)-one (AMG 221) J. Med. Chem. 2010, 53, 4481-4187
13. Siu, M.; Johnson, T. O.; Wang, Y.; Nair, S. K.; Taylor, W. D.; Cripps, S. J.; Matthews, J. J.; Edwards, M. P.; Pauly, T. A.; Ermolieff, J.; Castro, A.; Hosea, N. A.; LaPaglia, A.; Fanjul, A. N.; Vogel, J. E. N -(Pyridin-2-yl) arylsulfonamide inhibitors of 11β-hydroxysteroid dehydrogenase type 1: Discovery of PF-915275 Bioorg. Med. Chem. Lett. 2009, 19, 3493-3497
14. Rosenstock, J.; Banarer, S.; Fonseca, V. A.; Inzucchi, S. E.; Sun, W.; Yao, W.; Hollis, G.; Flores, R.; Levy, R.; Williams, W.; Seckl, J. R.; Huber, R. The 11β-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy Diabetes Care 2010, 33, 1516-1522
15. Shah, S.; Hermanowski-Vosatka, A.; Gibson, K.; Ruck, R. A.; Jia, G.; Zhang, J.; Hwang, P. M. T.; Ryan, N. W.; Langdon, R. B.; Feig, P. U. Efficacy and safety of the selective 11β-HSD-1 inhibitors MK-0736 and MK-0916 in overweight and obese patients with hypertension J. Am. Soc. Hypertens. 2011, 5, 166-176
16. Sun, W.; Maletic, M.; Mundt, S. S.; Shah, K.; Zokian, H.; Lyons, K.; Waddell, S. T.; Balkovec, J. Substituted phenyl triazoles as selective inhibitors of 11β-hydroxysteroid dehydrogenase type 1 Bioorg. Med. Chem. Lett. 2011, 21, 2141-2145
17. Xu, Z.; Tice, C. M.; Zhao, W.; Cacatian, S.; Ye, Y.; Singh, S. B.; Lindblom, P.; McKeever, B. M.; Krosky, P. M.; Kruk, B. A.; Berbaum, J.; Harrison, R. K.; Johnson, J. A.; Bukhtiyarov, Y.; Panemangalore, R.; Scott, B. B.; Zhao, Y.; Bruno, J. G.; Togias, J.; Guo, J.; Guo, R.; Carroll, P. J.; McGeehan, G. M.; Zhuang, L.; He, W.; Claremon, D. A. Structure-based design and synthesis of 1,3-oxazinan-2-one inhibitors of 11β-hydroxysteroid dehydrogenase type 1 J. Med. Chem. 2011, 54, 6050-6062
18. Scott, J. S.; Bowker, S. S.; deSchoolmeester, J.; Gerhardt, S.; Hargreaves, D.; Kilgour, E.; Lloyd, A.; Mayers, R. M.; McCoull, W.; Newcombe, N. J.; Ogg, D.; Packer, M. J.; Rees, A.; Revill, J.; Schofield, P.; Selmi, N.; Swales, J. G.; Whittamore, P. R. O. Novel acidic 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor with reduced acyl glucuronide liability: The discovery of 4-[4-(2-adamantylcarbamoyl)-5- tert -butyl-pyrazol-1-yl]benzoic acid (AZD8329) J. Med. Chem. 2012, 55, 10136-10147
19. Yu, J.; Liu, H.; Xia, G.; Liu, L.; Xu, Z.; Chen, Q.; Ma, C.; Sun, X.; Xu, J.; Li, H.; Li, P.; Shi, Y.; Xiong, B.; Liu, X.; Shen, J. Discovery of 2-Alkyl-1-arylsulfonylprolinamides as 11β-hydroxysteroid dehydrogenase type 1 Inhibitors ACS Med. Chem. Lett. 2012, 3, 793-798
20. Wan, Z.-K.; Chenail, E.; Li, H.; Ipek, M.; Xiang, J.; Suri, V.; Hahm, S.; Bard, J.; Svenson, K.; Xu, X.; Tian, X.; Wang, M.; Li, X.; Johnson, C. E.; Qadri, A.; Panza, D.; Perreault, M.; Mansour, T. S.; Tobin, J. F.; Saiah, E. Discovery of HSD-621 as a potential agent for the treatment of type 2 diabetes ACS Med. Chem. Lett. 2013, 2, 118-123
21. Bauman, D. R.; Whitehead, A.; Contino, L. C.; Cui, J.; Garcia-Calvo, M.; Gu, X.; Kevin, N.; Ma, X.; Pai, L.; Shah, K.; Shen, X.; Stribling, S.; Zokian, H. J.; Metzger, J.; Shevell, D. E.; Waddell, S. T. Evaluation of selective inhibitors of 11β-HSD1 for the treatment of hypertension Bioorg. Med. Chem. Lett. 2013, 23, 3650-3653
22. Wang, H.; Robl, J. A.; Hamann, L. G.; Simpkins, L. M.; Golla, R.; Li, X.; Seethala, R.; Zvyaga, T.; Gordon, D. A.; Robl, J. A.; Li, J. L. Generation of 3,8-substituted 1,2,4-triazolopyridines as potent inhibitors of human 11β-hydroxysteroid dehydrogenase type-1 Bioorg. Med. Chem. Lett. 2011, 21, 4146-4149
23. Zhu, Y.; Olson, S. H.; Graham, D.; Patel, G.; Hermanowski-Vosatka, A.; Mundt, S.; Shah, K.; Springer, M. Phenylcyclobutyl triazoles as selective inhibitors of 11β-hydroxysteroid dehydrogenase type I Bioorg. Med. Chem. Lett. 2008, 18, 3412-3416
24. The software used for this purpose was Glide SP as implemented in Maestro verson 9.0 (Glide, version 5.7, Schrodinger, LLC, New York, NY, 2011. Friesner, R. A.; Banks, J. L.; Murphy, R. B.; Halgren, T. A.; Klicic, J. J.; Mainz, D. T.; Repasky, M. P.; Knoll, E. H.; Shaw, D. E.; Shelley, M.; Perry, J. K.; Francis, P.; Shenkin, P. S. Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy J. Med. Chem. 2004, 47, 1739-1749
25. Tu, H.; Powers, J. P.; Liu, J.; Ursu, S.; Sudom, A.; Yan, X.; Xu, H.; Meininger, D.; Degraffenreid, M.; He, X.; Jaen, J. C.; Sun, D.; Labelle, M.; Yamamoto, H.; Shan, B.; Walker, N. P.; Wang, Z. Distinctive molecular inhibition mechanisms for selective inhibitors of human 11β-hydroxysteroid dehydrogenase type 1 Bioorg. Med. Chem. Lett. 2008, 16, 8922-8931
26. Emsley, P.; Lokhamp, B.; Scott, W.; Cowtan, K. Features and development of coot Acta Crystallogr., Sect. D: Biol. Crystallogr. 2010, 66, 486-501
27. Johansson, L.; Fotsch, C.; Bartberger, M. D.; Castro, V. M.; Chen, M.; Emery, M.; Gustafsson, S.; Hale, C.; Hickman, D.; Homan, E.; Jordan, S. R.; Komorowski, R.; Li, A.; McRae, K.; Moniz, G.; Matsumoto, G.; Orihuela, C.; Palm, G.; Veniant, M.; Wang, M.; Williams, M.; Zhang, J. 2-Amino-1,3-thiazol-4(5 H)-ones as potent and selective 11β-hydroxysteroid dehydrogenase type 1 inhibitors: Enzyme-ligand co-crystal structure and demonstration of pharmacodynamic effects in C57Bl/6 mice J. Med. Chem. 2008, 51, 2933-2943